Northeast Pharmaceutical Group Co (SZSE:000597) ROCE %: 5.13% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:000597 Northeast Pharmaceutical Group Co Ltd SZSE:000597
62 GF Score
Price ¥4.74
GF Value ¥4.21
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Northeast Pharmaceutical Group Co ROCE %?

Northeast Pharmaceutical Group Co SZSE:000597 +0.64% 62 ROCE % is 5.13% as of Jun. 2026. GuruFocus rates SZSE:000597 with a GF Score™ of 62/100 and a GF Value™ of ¥4.21 (Modestly Overvalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Northeast Pharmaceutical Group Co's annualized ROCE % for the quarter that ended in Jun. 2026 was 5.13%.

Northeast Pharmaceutical Group Co  (SZSE:000597) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Northeast Pharmaceutical Group Co ROCE % Related Terms

Northeast Pharmaceutical Group Co ROCE % Historical Data

* Premium members only.

The historical data trend for Northeast Pharmaceutical Group Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northeast Pharmaceutical Group Co ROCE % Chart

Northeast Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.86 11.91 10.21 11.07 5.66

Northeast Pharmaceutical Group Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.95 4.72 5.01 2.45 5.13
SZSE:000597
62GF Score
Northeast Pharmaceutical Group Co Ltd SZSE:000597
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Northeast Pharmaceutical Group Co ROCE % Calculation

Northeast Pharmaceutical Group Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=354.426/( ( (14446.182 - 8256.924) + (12888.948 - 6563.781) )/ 2 )
=354.426/( (6189.258+6325.167)/ 2 )
=354.426/6257.2125
=5.66 %

Northeast Pharmaceutical Group Co's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=321.112/( ( (13589.995 - 7253.178) + (13577.717 - 7388.083) )/ 2 )
=321.112/( ( 6336.817 + 6189.634 )/ 2 )
=321.112/6263.2255
=5.13 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.13% mean?
Northeast Pharmaceutical Group Co (SZSE:000597) has a ROCE % of 5.13% as of Jun. 2026.
Is Northeast Pharmaceutical Group Co's ROCE % too high?
Northeast Pharmaceutical Group Co's current ROCE % is 5.13%. The Drug Manufacturers industry median ROCE % is 6.55. Northeast Pharmaceutical Group Co's value of 5.13% is 21.7% below this industry median. Overall, Northeast Pharmaceutical Group Co has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Northeast Pharmaceutical Group Co's ROCE % compare to ZTS?
Northeast Pharmaceutical Group Co's ROCE % of 5.13% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 6.55. Northeast Pharmaceutical Group Co's value of 5.13% is 21.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 6.55, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Northeast Pharmaceutical Group Co's current ROCE % of 5.13% is 21.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 6.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Northeast Pharmaceutical Group Co's current ROCE % is 5.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northeast Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Northeast Pharmaceutical Group Co (SZSE:000597) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥4.21, compared to a current price of ¥4.74 — trading 12.6% above its estimated fair value. The current ROCE % is 5.13% and 21.7% below the Drug Manufacturers industry median of 6.55. Northeast Pharmaceutical Group Co's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Northeast Pharmaceutical Group Co (SZSE:000597), the current ROCE % is 5.13% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Northeast Pharmaceutical Group Co (SZSE:000597) Overvalued in 2026?

Based on GuruFocus' analysis, Northeast Pharmaceutical Group Co stock appears to be overvalued. The current stock price of ¥4.74 is trading 12.6% above its estimated GF Value™ of ¥4.21. GuruFocus considers Northeast Pharmaceutical Group Co to be Modestly Overvalued.

Key valuation signals for SZSE:000597:

  • ROCE %: 5.13%
  • GF Value™: ¥4.21 vs. price of ¥4.74 (12.6% above fair value)
  • GF Score™: 62/100 with 5 warning signs
  • Industry Position: 21.7% below the Drug Manufacturers median

No single metric tells the full story. See the SZSE:000597 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Northeast Pharmaceutical Group Co Business Description

Address No. 8 Kunminghu Street, Economic and Technology Development Zone, Shenyang, Liaoning, CHN, 110027
Northeast Pharmaceutical Group Co Ltd is engaged in the production and distribution of ammonium phosphate, sulfuric acid, cement, compound fertilizer, bromine, raw salt, and diammonium phosphate.
62GF Score

Get the complete analysis for SZSE:000597

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.74
Price
¥4.21
GF Value